Haleos Labs Limited — 360° view

Haleos Labs Limited, a company in the Pharmaceuticals industry, reported revenue of ₹91 crore and net profit of ₹1.76 crore for the September 2026 quarter.

Haleos Labs Limited (NSE: HALEOSLABS) closed at ₹1,610.80 on 20 Nov 2026, up 18.9% over the past year. Its market capitalisation is ₹487 crore and it trades at 37.5 times earnings.

Share price
₹1,610.80 (20 Nov 2026)
Market cap
₹487 Cr (20 Nov 2026)
P/E
37.55 (20 Nov 2026)
Revenue
₹91 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
9.94% (FY26)
ROE
8.44% (FY26)
Book value
₹725 (FY26)
Dividend yield
0.09% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,774.00 / ₹1,091.10 (20 Nov 2026)
1-year return
18.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: HALEOSLABS

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.